ArticleNature chemical biology2026
Achieving cell-type-specific bioorthogonal chemistry using enzyme-activated caged tetrazines.
Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bioorthogonal chemistry for deciphering lipid biology in living systems.RSC chemical biology · 2026Review
- Red light-responsive bioorthogonal chemistry enabled on-demand prodrug activation for cancer therapy.Acta pharmaceutica Sinica. B · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bioorthogonal reactions have revolutionized molecular biology through the conjugation of molecules within cellular environments. However, classical bioorthogonal reagents often suffer from nonspecific reactivity across diverse physiological contexts, diminishing their precision. This limitation presents considerable challenges in complex biological systems where multiple cell types coexist. Here we demonstrate tetrazine release and activation by cellular enzymes (TRACE), a method enabling cell-type-specific bioorthogonal chemistry. TRACE uses caged dihydrotetrazine derivatives, which remain inert until activated by specific cellular enzymes. Optimizing the electronic properties of the dihydrotetrazine scaffold enables rapid uncaging and activation of tetrazines within minutes. We demonstrate the utility of TRACE for the targeted release of cytotoxic drugs, selectively impacting the viability of enzyme-expressing cells in cocultures. Additionally, our method facilitates the delivery of imaging agents to subcellular structures in an enzyme-activity-dependent manner. TRACE represents a promising approach for programmable bioorthogonal chemistry in therapeutic and imaging applications.
Indexed as
Identifiers
42236587What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.